Literature DB >> 29045633

Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice.

Shanat Baig1,2, Nicky C Edward1,2, Dipak Kotecha1,2, Boyang Liu1,2, Sabrina Nordin3,4, Rebecca Kozor5, James C Moon3,4, Tarekegn Geberhiwot6, Richard P Steeds1,2.   

Abstract

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficiency of α-galactosidase A enzyme. Cardiovascular (CV) disease is a common cause of mortality in FD, in particular as a result of heart failure and arrhythmia, with a significant proportion of events categorized as sudden. There are no clear models for risk prediction in FD. This systematic review aims to identify the risk factors for ventricular arrhythmia (VA) and sudden cardiac deaths (SCD) in FD. A systematic search was performed following PRISMA guidelines of EMBASE, Medline, PubMed, Web of Science, and Cochrane from inception to August 2016, focusing on identification of risk factors for the development of VA or SCD. Thirteen studies were included in the review (n = 4185 patients) from 1189 articles, with follow-up of 1.2-10 years. Weighted average age was 37.6 years, and 50% were male. Death from any cause was reported in 8.3%. Of these, 75% was due to CV problems, with the majority being SCD events (62% of reported deaths). Ventricular tachycardia was reported in 7 studies, with an average prevalence of 15.3%. Risk factors associated with SCD events were age, male gender, left ventricular hypertrophy, late gadolinium enhancement on CV magnetic resonance imaging, and non-sustained ventricular tachycardia. Although a multi-system disease, FD is a predominantly cardiac disease from a mortality perspective, with death mainly from SCD events. Limited evidence highlights the importance of clinical and imaging risk factors that could contribute to improved decision-making in the management of FD.

Entities:  

Mesh:

Year:  2018        PMID: 29045633     DOI: 10.1093/europace/eux261

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  18 in total

1.  Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional study.

Authors:  Lu Zhao Di; Maxime Pichette; Réginald Nadeau; Daniel G Bichet; Frédéric Poulin
Journal:  Clin Cardiol       Date:  2018-09-20       Impact factor: 2.882

Review 2.  Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

Authors:  Aleš Linhart; Tomáš Paleček
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 3.  Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review.

Authors:  Álvaro Arbeláez-Cortés; Diana C Quintero-González; Yesid Cuesta-Astroz; Juan S Villadiego; Herman González-Buriticá; Jorge M Rueda
Journal:  Rheumatol Int       Date:  2019-10-10       Impact factor: 2.631

4.  Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY.

Authors:  Antoine Asquier-Khati; Wladimir Mauhin; Guillaume Michel; Adrien Gendre; Cécile Durant; Christian Lavigne; Hélène Maillard; Didier Lacombe; Marjolaine Willems; Olivier Lidove; Agathe Masseau
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-26       Impact factor: 2.503

Review 5.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

6.  Cardiac Phenotype of Prehypertrophic Fabry Disease.

Authors:  Sabrina Nordin; Rebecca Kozor; Shanat Baig; Amna Abdel-Gadir; Katia Medina-Menacho; Stefania Rosmini; Gabriella Captur; Michel Tchan; Tarekegn Geberhiwot; Elaine Murphy; Robin Lachmann; Uma Ramaswami; Nicola C Edwards; Derralynn Hughes; Richard P Steeds; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2018-06       Impact factor: 7.792

7.  A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice.

Authors:  Ravi Vijapurapu; Rebecca Kozor; Derralynn A Hughes; Peter Woolfson; Ana Jovanovic; Patrick Deegan; Rosemary Rusk; Gemma A Figtree; Michel Tchan; David Whalley; Dipak Kotecha; Francisco Leyva; James Moon; Tarekegn Geberhiwot; Richard P Steeds
Journal:  Trials       Date:  2019-05-31       Impact factor: 2.279

8.  Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy.

Authors:  Ravi Vijapurapu; Tarekegn Geberhiwot; Ana Jovanovic; Shanat Baig; Sabrina Nordin; Rebecca Kozor; Francisco Leyva; Dipak Kotecha; Nigel Wheeldon; Patrick Deegan; Rosemary A Rusk; James C Moon; Derralynn A Hughes; Peter Woolfson; Richard P Steeds
Journal:  Heart       Date:  2019-08-24       Impact factor: 5.994

9.  The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.

Authors:  João B Augusto; Nicolas Johner; Dipen Shah; Sabrina Nordin; Kristopher D Knott; Stefania Rosmini; Clement Lau; Mashael Alfarih; Rebecca Hughes; Andreas Seraphim; Ravi Vijapurapu; Anish Bhuva; Linda Lin; Natalia Ojrzyńska; Tarekegn Geberhiwot; Gabriella Captur; Uma Ramaswami; Richard P Steeds; Rebecca Kozor; Derralynn Hughes; James C Moon; Mehdi Namdar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

Review 10.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.